Recombinant NKG2A (Monalizumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA, WB
Host: Humanized
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all NKG2A (Monalizumab Biosimilar) products
- NKG2A (Monalizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Humanized
- Expression System
- Mammalian cells
-
Clonality
- Monoclonal
-
Conjugate
- This NKG2A (Monalizumab Biosimilar) antibody is un-conjugated
- Application
- ELISA, Western Blotting (WB)
- Purpose
- Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade
- Characteristics
- Antibody Type: IgG4-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Purity
- > 85%
- Grade
- Research Grade
- Isotype
- IgG4
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS buffer PH7.5
- Storage
- -80 °C
- Storage Comment
- store at -80°C
-
- Target
- NKG2A (Monalizumab Biosimilar)
- Abstract
- NKG2A (Monalizumab Biosimilar) Products
- Background
- Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
- CAS-No
- 1228763-95-8
-
You are here:
